This Article Full Text (PDF) All Versions of this Article: 0962280207081861v1 17/5/505    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baker, S. G Search for Related Content PubMed PubMed Citation Articles by Baker, S. G Social Bookmarking                         What's this?

Two simple approaches for validating a binary surrogate endpoint using data from multiple trials

Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA, sb16i{at}nih.gov

A surrogate endpoint is an endpoint that is observed before a true endpoint and is used to draw conclusions about the effect of intervention on true endpoint. To gauge confidence in the use of a surrogate endpoint, it must be validated. Two simple validation methods using data from multiple trials with surrogate and true endpoints are discussed: an estimation method extending previous work and new method based on hypothesis tests. The validation methods were applied to two data sets, each involving 10 randomized trials: one for patients with early colon cancer where the true endpoint was survival status at eight years and surrogate endpoint was cancer recurrence status at three years, and one for patients with advanced colorectal cancer where the true endpoint was survival status at 12 months and the surrogate endpoint was cancer recurrence status at six months. The estimation method uses the surrogate endpoint in the new trial and a model relating surrogate and true endpoints in previous trials to predict the effect of intervention on true endpoint in the new trial. For validation, each trial was successively treated as the `new' trial and a comparison was made between predicted and observed effects of intervention on true endpoint. Performance of the surrogate endpoint was good in both data sets. The hypothesis testing method involves the z-statistic for the surrogate endpoint, which is the estimated effect of intervention on surrogate endpoint divided by its standard error. To use this z-statistic to test a null hypothesis of no effect of intervention on true endpoint, the critical value is increased above a standard level of 1.96 to a level determined by the relationships between surrogate and true endpoints in the data sets. This elevated critical value could be used for accelerated approval.

This version was published on October 1, 2008

Statistical Methods in Medical Research, Vol. 17, No. 5, 505-514 (2008)
DOI: 10.1177/0962280207081861


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Piedbois and J. Miller Croswell Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective Statistical Methods in Medical Research, October 1, 2008; 17(5): 519 - 527. [Abstract] [PDF]